Avalo Therapeutics completes target enrollment in Phase 2 PEAK trial

Avalo Therapeutics completed enrollment of the 80 patients targeted for the Phase 2 PEAK Trial evaluating AVTX-002 in patients with Non-Eosinophilic Asthma. Avalo will allow additional patients currently in the run-in period to complete enrollment. Topline data from the clinical trial are expected to be released in the second quarter of 2023. The Phase 2 PEAK Trial is a randomized, double-blind, placebo-controlled, parallel group trial designed to evaluate the safety and efficacy of AVTX-002 for the treatment of poorly controlled NEA. Following 12 weeks of treatment, the efficacy and safety of AVTX-002 will be evaluated compared with placebo. The primary endpoint is the proportion of patients who experience any of the following asthma-related events: greater than or equal to6 additional reliever puffs of a short-acting beta-agonist in a 24-hour period on 2 consecutive days, or increase in inhaled corticosteroid dose greater than or equal to4 times than the dose at baseline, or a decrease in peak flow of 30% or more on 2 consecutive days of treatment, or an asthma exacerbation requiring the use of systemic corticosteroids for at least 3 days, or a hospitalization or emergency room visit because of an asthma exacerbation.